Joel S. Perlmutter, M.D.

(current MEDLINE for all authors named "J. S. Perlmutter")

SELECTED PUBLICATIONS:

  1. Perlmutter JS, Raichle ME: Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. Ann Neurol 15:228-233, 1984.
  2. Fox PT, Perlmutter JS, Raichle ME: A stereotactic method of anatomical localization for positron emission tomography. JCAT 9:141-153, 1985.
  3. Perlmutter JS, Raichle ME: Regional blood flow in hemiparkinsonism. Neurology 35:1127-1134, 1985.
  4. Perlmutter JS, Raichle ME: In vitro or in vivo receptor binding: where does the truth lie? Ann Neurol 19:384-385, 1986.
  5. Perlmutter JS, Larson KB, Raichle ME, Markham J, Mintun MA, Kilbourn MR, Welch MJ: Strategies for the in vivo measurement of receptor binding using positron emission tomography. JCBFM 6:154-169, 1986.
  6. Perlmutter JS, Kilbourn MR, Raichle ME, Welch MJ: MPTP induced up-regulation of in vivo dopaminergic radioligand-receptor binding in man. Neurology 37:1575-1579, 1987.
  7. Perlmutter, JS: New insights into the pathophysiology of Parkinson's Disease: the challenge of positron emission tomography. TINS 11:203-208, 1988.
  8. Videen TO, Perlmutter JS, Mintun MA, Raichle ME: Regional correction of positron emission tomography data for the effects of cerebral atrophy. JCBFM. 8:662-670, 1988
  9. Perlmutter JS, Kilbourn MR, Welch MJ, Raichle ME: Nonsteady-state measurement of in vivo receptor binding with positron emission tomography: "dose-response" analysis. J Neurosci. 9:2344-2352, 1989.
  10. Tempel L, Perlmutter J: Abnormal vibration-induced cerebral blood flow response in dystonia Brain 113:691-707,1990.
  11. Perlmutter JS, Lich LL, Margenau W, Buchholz S: PET measured evoked cerebral blood flow responses in an awake monkey. JCBFM 11:229-235, 1991.
  12. Moerlein SM, Perlmutter JS: Evaluation of [F-18]fluoroethylketanserin for in vivo measurement of serotonergic S2 binding in brain with PET. Neurosci Ltr 123:23-26, 1991.
  13. Perlmutter JS, Moerlein SM, Huang D-R, Todd R: Non-steady-state measurement of in vivo radioligand binding with positron emission tomography: specificity analysis and comparison with in vitro binding. J Neurosci 11:1381-1389, 1991.
  14. Powers, WJ, Perlmutter JS, Videen TO, Herscovitch P, Griffeth LK, Royal HD, Siegel BA, Morris JC, Berg L: Blinded clinical evaluation of positron emission tomography for diagnosis of Alzheimer's disease. Neurology 42:765-770, 1992.
  15. Moerlein SM, Perlmutter JS: Binding of 5-(2'-[18F] fluoroethyl) flumazenil to central benzodiazepine receptors measured in living baboon with positron emission tomography. Eur J Pharmacol 218:109-115, 1992.
  16. Perman WH, Gado MH, Larson KB, Perlmutter JS: Simultaneous MR acquisition of arterial and brain signal-time curves. Mag Res Med 28:74-83, 1992.
  17. Tempel LW, Perlmutter JS: Vibration-induced regional CBF responses in healthy aging. JCBFM 12:554-561, 1992.
  18. Moerlein SM, Perlmutter JS: Specific binding of 3N-(2'-[18F]fluoroethyl)benperidol to primate cerebral dopaminergic D2 receptors demonstrated in vivo by PET. Neurosci Lett 148: 97-100, 1992.
  19. Perman WH, El-Ghazzawy O, Gado MH, Larson KB, Perlmutter JS: A half-fourier gradient echo technique for dynamic MR imaging. Mag Res Imag, 11: 357-366, 1993.
  20. Tempel LW, Perlmutter JS: Abnormal cortical responses to vibration in patients with writer's cramp Neurol 43:2252-2257, 1993.
  21. Perlmutter JS: New techniques in neuroimaging: When are pretty pictures clinically useful? Current Opinion in Neurol & Neurosurg. 6(6): 889-890, (Neuroimaging section editor-JS Perlmutter) 1993.
  22. Larson KB, Perman WH, Perlmutter JS, Gado MH: Tracer-kinetic analysis for measuring regional cerebral-blood flow by dynamic nuclear magnetic resonance imaging. J Theoretical Biology 170:1-14, 1994.
  23. Moerlein SM, Perlmutter JS, Welch MJ, Raichle ME: First-pass extraction fraction of iodine-123 labeled perfusion tracers in living primate brain. Nucl Med Biol 21:847-855, 1994.
  24. Martin WRW, Perlmutter JS: Assessment of fetal transplantation in Parkinson's Disease: Does PET play a role? Neurology 44:1777-1780, 1994.
  25. Moerlein SM, Perlmutter JS, Welch MJ: USP standards for raclopride C11 injection. Pharm Forum 21:172-176, 1995.
  26. Perlmutter JS: PET evaluation of dopaminergic pathways. Clin Neuropharmacol 18:S188-194, 1995.
  27. Moerlein SM, Perlmutter JS, Welch MJ: Specific, reversible binding of [18F] benperidol to baboon D2 receptors: PET evaluation of an improved 18F-labeled ligand. Nucl Med Biol 22:809-815, 1995.
  28. Black KJ, Videen TO, Perlmutter JS: A metric for testing the accuracy of cross-modality image registration: validation and application. J Comput Assist Tomogr. 20:855-861, 1996.
  29. Todd RD, Carl J, Harmon S, O'Malley KL, Perlmutter JS: Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to MPTP denervation in baboons. J Neurosci 16:7776-7782, 1996
  30. Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, Moerlein SM: Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 17:834-842, 1997.
  31. Perlmutter JS: Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers: A commentary. Neurology Network Commentary 1:57-61,1997.
  32. Black KJ, Gado MH, Perlmutter JS: PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function. J Neurosci. 17:3168-3177, 1997.
  33. Black KJ, Perlmutter JS: Septuagenarian Sydenham's: recurrence of chorea with secondary hypomania after 61 asymptomatic years. Neuropsychiatry Neuropsychology Behavioral Neurology 10(2):147-150, 1997.
  34. Moerlein SM, Perlmutter JS, Cutler PD, Welch MJ: Radiation dosimetry of [18F](n-methyl)benperidol as determined by whole-body pet imaging of primates. Nucl Med Biol. 24:311-318, 1997.
  35. Moerlein SM, Perlmutter JS, Welch MJ: In vivo kinetics of [18F](N-methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2 receptor binding. JCBFM. 17:833-845, 1997.
  36. Black KJ, Gado JH, Videen TO, Perlmutter JS: Baboon basal ganglia stereotaxy using internal MRI landmarks: validation and application to PET imaging. JCAT 21:881-886, 1997.
  37. Perlmutter JS, Tempel LW, Black KJ, Parkinson D, Todd RD: MPTP induces dystonia & parkinsonism: clues to the pathophysiology of dystonia. Neurology 49:1432-1438, 1997.
  38. Black KJ, Perlmutter JS: Can FDOPA PET help determine disease status in familial Parkinson's disease? Neurology Network Commentary. 1:308-314, 1997.
  39. Racette BA, Lauryssen C, Perlmutter JS: Preoperative botulinum toxin injections permit cervical fusion in dystonic cerebral palsy. J Neurosurg 88:328-330,1998
  40. Todd RD, Perlmutter JS: Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition. Mol Neurobiol (in press).
  41. Black K, Perlmutter J, Racette B: Botulinum toxin treatment to prevent contractures in NMS. Am J Psychiatr (in press)
  42. Parsian A, Racette B, Zhang Z, Rundle M, Perlmutter JS: Association studies of cytochrome P450IID6 polymorphisms with familial and sporadic Parkinson's disease. (in press).
  43. Moerlein SM, Mintun MA, Perlmutter JS, Welch MJ, Siegel BS: USP Standards for flumazenil C11 injection. 1998 (in press)
  44. Racette BA, Perlmutter JS: Levodopa responsive parkinsonism in an adult with Huntington disease. J Neurol Neurosurg Psychiatr 1998 (in press).